Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review
- PMID: 32956162
- PMCID: PMC7864607
- DOI: 10.1097/ADM.0000000000000739
Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review
Abstract
Objectives: Although medications for opioid use disorder (MOUD) save lives, treatment retention remains challenging. Identification of interventions to improve MOUD retention is of interest to policymakers and researchers. On behalf of the Agency for Healthcare Research and Quality, we conducted a rapid evidence review on interventions to improve MOUD retention.
Methods: We searched MEDLINE and the Cochrane Library from February 2009 through August 2019 for systematic reviews and randomized trials of care settings, services, logistical support, contingency management, health information technology (IT), extended-release (XR) formulations, and psychosocial interventions that assessed retention at least 3 months.
Results: Two systematic reviews and 39 primary studies were included; most did not focus on retention as the primary outcome. Initiating MOUD in soon-to-be-released incarcerated people improved retention following release. Contingency management may improve retention using antagonist but not agonist MOUD. Retention with interventions integrating medical, psychiatric, social services, or IT did not differ from in-person treatment-as-usual approaches. Retention was comparable with XR- compared to daily buprenorphine formulations and conflicting with XR-naltrexone monthly injection compared to daily buprenorphine. Most psychosocial interventions did not improve retention.
Discussion: Consistent but sparse evidence supports criminal justice prerelease MOUD initiation, and contingency management interventions for antagonist MOUD. Integrating MOUD with medical, psychiatric, social services, delivering through IT, or administering via XR-MOUD formulations did not worsen retention. Fewer than half of the studies we identified focused on retention as a primary outcome. Studies used different measures of retention, making it difficult to compare effectiveness. Additional inquiry into the causes of low retention would inform future interventions.Registration: PROSPERO: CRD42019134739.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine.
Conflict of interest statement
The authors report no conflicts of interest.
Figures
Comment in
-
Initiation of Medications for Opioid Use Disorder Shortly Before Release From Prison to Promote Treatment Retention: Strong Evidence but Compromised Policy.J Addict Med. 2021 Nov-Dec 01;15(6):525-526. doi: 10.1097/ADM.0000000000000788. J Addict Med. 2021. PMID: 33298751 No abstract available.
-
Letter in Reply.J Addict Med. 2021 Nov-Dec 01;15(6):526-527. doi: 10.1097/ADM.0000000000000787. J Addict Med. 2021. PMID: 33298752 No abstract available.
Similar articles
-
Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Jul. Report No.: 20-EHC012. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Jul. Report No.: 20-EHC012. PMID: 32775956 Free Books & Documents. Review.
-
Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.J Subst Use Addict Treat. 2024 Jun;161:209248. doi: 10.1016/j.josat.2023.209248. Epub 2023 Dec 9. J Subst Use Addict Treat. 2024. PMID: 38081540
-
Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.JAMA Netw Open. 2023 Apr 3;6(4):e237036. doi: 10.1001/jamanetworkopen.2023.7036. JAMA Netw Open. 2023. PMID: 37058306 Free PMC article.
-
Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.JAMA Netw Open. 2022 May 2;5(5):e2211363. doi: 10.1001/jamanetworkopen.2022.11363. JAMA Netw Open. 2022. PMID: 35536575 Free PMC article.
-
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.Addict Behav. 2023 Apr;139:107589. doi: 10.1016/j.addbeh.2022.107589. Epub 2022 Dec 17. Addict Behav. 2023. PMID: 36565531 Review.
Cited by
-
Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model.PLoS One. 2024 Aug 29;19(8):e0308102. doi: 10.1371/journal.pone.0308102. eCollection 2024. PLoS One. 2024. PMID: 39208211 Free PMC article. Clinical Trial.
-
Linkage facilitation for opioid use disorder in criminal legal system contexts: a primer for researchers, clinicians, and legal practitioners.Health Justice. 2024 Aug 29;12(1):36. doi: 10.1186/s40352-024-00291-8. Health Justice. 2024. PMID: 39207608 Free PMC article.
-
Assessing the impact of jail-initiated medication for opioid use disorder: A multisite analysis of the SOMATICS collaborative.PLoS One. 2024 Jun 17;19(6):e0305165. doi: 10.1371/journal.pone.0305165. eCollection 2024. PLoS One. 2024. PMID: 38885220 Free PMC article. Clinical Trial.
-
Effect of the Communities that HEAL intervention on receipt of behavioral therapies for opioid use disorder: A cluster randomized wait-list controlled trial.Drug Alcohol Depend. 2024 Jun 1;259:111286. doi: 10.1016/j.drugalcdep.2024.111286. Epub 2024 Apr 5. Drug Alcohol Depend. 2024. PMID: 38626553 Clinical Trial.
-
Training in Substance use Disorders, Part 1: Overview of Clinical Practice Recommendations.Can J Psychiatry. 2024 Jun;69(6):428-456. doi: 10.1177/07067437241231128. Epub 2024 Apr 13. Can J Psychiatry. 2024. PMID: 38613369 No abstract available.
References
-
- Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder 2018. - PubMed
-
- National Academies of Sciences Engineering, Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press; 2019. - PubMed
-
- Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry 2019; 76 (2):208–216. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
